Saphenous vein grafts (SVGs) are the most widely employed conduits for coronary artery bypass graft surgery (CABG) surgeries. However, SVG failure due to reduced patency (the ability for the vessel to remain an open conduit for blood flow) is a persistent and significant clinical problem, particularly in patients with diabetes. The advancement of coronary artery disease and diminishing SVG patency are strongly influenced by high low-density cholesterol (LDL-C) levels and accordingly, all major guidelines endorse aggressive LDL-C lowering in people who have or are at high risk of developing atherosclerotic cardiovascular disease. Evolocumab is a PCSK9 inhibitor that has been particularly useful in reducing LDL-C beyond the benefits of more traditional statin medications. NEWTON-CABG CardioLink-5 is a multicenter, global, double-blind, randomized, placebo-controlled, parallel group study evaluating the effect of evolocumab on SVG patency following CABG surgery. Enrollment has been completed and follow-ups are ongoing.
View details on ClinicalTrials.gov
